Cancer pharmacogenomics: SNPs, chips, and the individual patient

Cancer Investigation

Volumn 21, Issue 4, 2003, Pages 630-640

  McLeod, Howard L ^a,b   Yu, Jinsheng ^a  

^a Washington University in St Louis   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

Cancer therapeutics; Pediatric oncology; Pharmacogenetics; Pharmacogenomics

Indexed keywords

MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE;

CANCER THERAPY; DRUG DISPOSITION; DRUG EFFECT; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN GENOME; INDIVIDUALITY; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

6-MERCAPTOPURINE; ANTIMETABOLITES, ANTINEOPLASTIC; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HUMANS; MEDICAL ONCOLOGY; METHYLTRANSFERASES; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATIENT CARE PLANNING; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; VARIATION (GENETICS);

EID: 0141565216     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120022384     Document Type: Review

References (45)

1. Evans, W.E.; Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286, 487-491.
2. McLeod, H.L.; Evans, W.E. Pharmacogenomics: unlocking the human genome for better therapy. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 101-121.
3. Sachidanandam, R.; Weissman, D.; Schmidt, S.C.; Kakol, J.M.; Stein, L.D. ; Marth, G.; Sherry, S.; Mullikin, J.C.; Mortimore, B.J.; Willey, D.L.; Hunt, S.E.; Cole, C.G.; Coggill, P.C.; Rice, C.M.; Ning, Z.; Rogers, J.; Bentley, D.R.; Kwok, P.Y.; Mardis, E.R.; Yeh, R.T.; Schultz, B.; Cook, L.; Davenport, R. ; Dante, M.; Fulton, L.; Hillier, L.; Waterston, R.H.; McPherson, J.D.; Gilman, B.; Schaffner, S.; Van Etten, W.J.; Reich, D.; Higgins, J.; Daly, M.J.; Blumenstiel, B.; Baldwin, J.; Stange-Thomann, N.; Zody, M.C.; Linton, L.; Lander, E.S.; Atshuler, D. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001, 409, 928-933.
4. Brown, P.O.; Botstein, D. Exploring the new world of the genome with DNA microarrays. Nat. Genet. 1999, 21, 33-37.
5. Scherf, U.; Ross, D.T.; Waltham, M.; Smith, L.H.; Lee, J.K.; Tanabe, L.; Kohn, K.W.; Reinhold, W.C.; Myers, T.G.; Andrews, D.T.; Scudiero, D.A.; Eisen, M.B.; Sausville, E.A.; Pommier, Y.; Botstein, D.; Brown, P.O.; Weinstein, J.N. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 2000, 24, 236-244.
6. Marton, M.J.; DeRisi, J.L.; Bennett, H.A.; Iyer, V.R.; Meyer, M.R.; Roberts, C.J.; Stoughton, R.; Burchard, J.; Slade, D.; Dai, H.; Bassett, D.E., Jr.; Hartwell, L.H.; Brown, P.O.; Friend, S.H. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat. Med. 1998, 4, 1293-1301.
7. Perou, C.M.; Sorlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; Fluge, O.; Pergamenschikov, A.; Williams, C.; Zhu, S.X.; Lonning, P.E.; Borresen-Dale, A.L.; Brown, P.O.; Botstein, D. Molecular portraits of human breast tumours. Nature 2000, 406, 747-752.
8. Golub, T.R.; Slonim, D.K.; Tamayo, P.; Huard, C.; Gaasenbeek, M.; Mesirov, J.P.; Coller, H.; Loh, M.L.; Downing, J.R.; Caliguiri, M.A.; Bloomfield, C.D.; Lander, E.S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286, 531-537.
9. Alizadeh, A.A.; Eisen, M.B.; Davis, R.E.; Chi, M.; Lossos, I.S.; Rosenwald, A.; Boldrick, J.C.; Sabet, H.; Tran, T.; Yu, X.; Powell, J.I.; Yang, L.; Marti, G.E.; Moore, T.; Hudson, J., Jr.; Lu, L.; Lewis, D.B.; Tibshirani, R.; Sherlock, G.; Chan, W.C.; Greiner, T.C.; Weisenburger, D.D.; Armitage, J.O. ; Wamke, R.; Levy, R.; Wilson, W.; Grever, M.R.; Byrd, J.C.; Botstein, D.; Brown, P.O.; Staudt, L.M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403, 503-511.
10. Hedenfalk, I.; Duggan, D.; Chen, Y.; Radmacher, M.; Bittner, M.; Simon, R.; Meltzer, P.; Gusterson, B.; Esteller, M.; Kallioniemi, O.P.; Wilfond, B.; Borg, A.; Trent, J. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 2001, 344, 539-548.
11. Kantoff, P.W.; Halabi, S.; Farmer, D.A.; Hayes, D.F.; Vogelzang, N.A.; Small, E.J. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J. Clin. Oncol. 2001, 15, 3025-3028.
12. Burchill, S.A.; Lewis, I.J.; Abrams, K.R.; Riley, R.; Imeson, J.; Pearson, A.D.; Pinkerton, R.; Selby, P. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J. Clin. Oncol. 2001, 19, 1795-1801.
13. Salonga, D.; Danenberg, K.D.; Johnson, M.; Metzger, R.; Groshen, S.; Tsao-Wei, D.D.; Lenz, H.J.; Leichman, C.G.; Leichman, L.; Diasio, R.B.; Danenberg, P.V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 2000, 6, 1322-1327.
14. Milano, G.; McLeod, H.L. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? Eur. J. Cancer 2000, 36, 37-42.
15. Rooney, P.H.; Murray, G.I.; Stevenson, D.A.; Haites, N.E.; Cassidy, J.; McLeod, H.L. Comparative genomic hybridization and chromosomal instability in solid tumours. Br. J. Cancer 1999, 80, 862-873.
16. Rooney, P.H.; Stevenson, D.A.; Marsh, S.; Johnston, P.G.; Haites, N.E.; Cassidy, J.; McLeod, H.L. Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors. Cancer Res. 1998, 58, 5042-5045.
17. Krynetski, E.Y.; Evans, W.E. Pharmacogenetics of cancer therapy: getting personal. Am. J. Hum. Genet. 1998, 63, 11-16.
18. McLeod, H.L.; Krynetski, E.; Relling, M.V.; Evans, W.E. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000, 14, 567-572.
19. Weinshilboum, R.M.; Sladek, S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 1980, 32, 651-662.
20. McLeod, H.L.; Relling, M.V.; Liu, Q.; Pui, C.-H.; Evans, W.E. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995, 85, 1897-1902.
21. Schutz, E.; Gummert, J.; Mohr, F.; Ollerich, M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993, 341, 436.
22. McLeod, H.L.; Miller, D.R.; Evans, W.E. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993, 341, 1151.
23. Krynetski, E.Y.; Schuetz, J.D.; Galpin, A.J.; Pui, C.-H.; Relling, M.V.; Evans, W.E. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl Acad. Sci. U.S.A. 1995, 92, 949-953.
24. Tai, H.L.; Krynetski, E.Y.; Yates, C.R.; Loennechen, T.; Fessing, M.Y.; Krynetskaia, N.F.; Evans, W.E. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am. J. Hum. Genet. 1996, 58, 694-702.
25. Loennechen, T.; Yates, C.R.; Fessing, M.Y.; Relling, M.V.; Krynetski, E.Y.; Evans, W.E. Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. Clin. Pharmacol. Ther. 1998, 64, 46-51.
26. Tai, H.L.; Krynetski, E.Y.; Schuetz, E.G.; Yanishevski, Y.; Evans, W.E. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl Acad. Sci. U.S.A. 1997, 94, 6444-6449.
27. Yates, C.R.; Krynetski, E.Y.; Loennechen, T.; Fessing, M.Y.; Tai, H.L.; Pui, C.H.; Relling, M.V.; Evans, W.E. Molecular diagnosis of thiopurine S-methyltransferase deficiency; genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 1997, 126, 608-614.
28. Ameyaw, M.M.; Collie-Duguid, E.S.; Powrie, R.H.; Ofori-Adjei, D.; McLeod, H.L. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum. Mol. Genet. 1999, 8, 367-370.
29. Hon, Y.Y.; Fessing, M.Y.; Pui, C.-H.; Relling, M.V.; Krynetski, E.Y.; Evans, W.E. Polymorphism of the thiopurine S-methyltransferase gene in African Americans. Hum. Mol. Genet. 1999, 8, 371-376.
30. Collie-Duguid, E.S.; Pritchard, S.C.; Powrie, R.H.; Sludden, J.; Li, T.; McLeod, H.L. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999, 9, 37-42.
31. Coulthard, S.A.; Howell, C.; Robson, J.; Hall, A.G. The relationship between thiopurine methyltrasferase activiy and genotype in blasts from patients with acute leukemia. Blood 1998, 92, 2856-2862.
32. Lennard, L.; Van Loon, J.A.; Weinshilboum, R.M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther. 1989, 46, 149-154.
33. Evans, W.E.; Horner, M.; Chu, Y.Q.; Kalwinsky, D.; Roberts, W.M. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J. Pediatr. 1991, 119, 985-989.
34. Black, A.J.; McLeod, H.L.; Capell, H.A.; Powrie, R.H.; Matowe, L.K.; Pritchard, S.C.; Collie-Duguid, E.S.; Reig, D.M. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann. Intern. Med. 1998, 129, 716-718.
35. Ishioka, S. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Inter. Med. 1999, 38, 944-947.
36. Relling, M.V.; Hancock, M.L.; Rivera, G.K.; Sandlund, J.T.; Ribeiro, R.C.; Krynetski, E.Y.; Pui, C.H.; Evans, W.E. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst. 1999, 91, 2001-2008.
37. Relling, M.V.; Yanishevski, Y.; Nemec, J.; Evans, W.E.; Boyett, J.M.; Behm, F.G.; Pui, C.H. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998, 12, 346-352.
38. Be, J.; Schreder, I.I.; Kristiesson, J.; Madsen, B.; Szumlanski, C.; Weinshilboum, R.; Andersen, J.B.; Schmieglow, K. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer 1999, 86, 1080-1086.
39. Relling, M.V.; Rubnitz, J.E.; Rivera, G.K.; Boyett, J.M.; Hancock, M.L.; Felix, C.A.; Kun, L.E.; Walter, A.W.; Evans, W.E.; Pui, C.H. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999, 354, 34-39.
40. Sindrup, S.H.; Brosen, K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995, 5, 335-346.
41. Poulsen, L.; Arendt-Nielsen, L.; Brosen, K.; Sindrup, S.H. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin. Pharmacol. Ther. 1996, 60, 636-644.
42. Iyer, L.; King, C.D.; Whitington, P.F.; Green, M.D.; Roy, S.K.; Tephly, T.R.; Coffman, B.L.; Ratain, M.J. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Investig. 1998, 101, 847-854.
43. Iyer, L.; Hall, D.; Das, S.; Mortell, M.A.; Ramirez, J.; Kim, S.; Di Rienzo, A.; Ratain, M.J. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 1999, 65, 576-582.
44. Ando, Y.; Saka, H.; Ando, M.; Sawa, T.; Muro, K.; Ueoka, H.; Yokovama, A.; Saitoh, S.; Shimokata, K.; Hasegawa, Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000, 60, 6921-6926.
45. Iyer, L.; Das, S.; Janisch, L.; Wen, M.; Ramirez, J.; Karrison, T.; Fleming, G.F.; Vokes, E.E.; Schilsky, R.L.; Ratain, M.J. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002, 2, in press.